October 07, 2019
Nordic Nanovector signs global clinical and commercial agreement with ITM for the supply of no-carrier-added Lutetium-177
Media
October 03, 2019
Vicore Pharma announces the Nomination Committee for the 2020 Annual General Meeting
October 02, 2019
Aprea Therapeutics Announces Pricing of Initial Public Offering
October 01, 2019
Update on progress in clinical lead program VP01 (C21)
October 01, 2019
GenSight Biologics integrates the Enternext® PEA-PME 150 index by Euronext
October 01, 2019
Nordic Nanovector appoints Dr Gabriele Elbl as Vice President Global Regulatory Affairs
September 26, 2019
Patient recruitment in the Pivotal Phase 2-Study HORIZON completed
September 25, 2019
Strongbridge Biopharma plc to Present at the 2019 Cantor Global Healthcare Conference
September 24, 2019
Targovax announces opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma
September 23, 2019
GenSight Biologics reports sustained efficacy and safety at 96 weeks in RESCUE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)